Quality of cord blood cryopreserved for up to 5 years

Hye Ryun Lee¹, Eun Young Song², Sue Shin²,³, ⁵, Eun Youn Roh²,³, ⁵, Jong Hyun Yoon²,³, ⁵, Byoung Jae Kim⁴

Department of Laboratory Medicine, ¹Gyeongsang National University Hospital, Jinju, ²Seoul National University College of Medicine, ³Department of Laboratory Medicine, ⁵Department of Obstetrics and Gynecology, Boramae Hospital, ⁶Seoul Metropolitan Government Public Cord Blood Bank (Allcord), Seoul, Korea

**Background**

Although cord blood (CB) is a well-known source of hematopoietic stem cells, uncertainties exist regarding the quality of cryopreserved CB. We investigated the changes in quality of CB units according to the duration of cryopreservation.

**Methods**

We analyzed CB units that were rejected from the Seoul Metropolitan Government Public Cord Blood Bank inventory after conventional processing, because of unsuitability for allogeneic transplantation. Two hundred CB units that were cryopreserved from 1 year to 5 years were selected. After thawing the cryopreserved CB units, the total nucleated cell (TNC) count, CD34+ cell count, number of colony-forming units (CFU), aldehyde dehydrogenase (ALDH) level, cell viability, and apoptosis were analyzed. We conducted a comparative analysis to identify the presence of statistically significant differences in the recovery rates of the TNC and CD34+ cell counts and to compare the results of ALDH level, the cell viability test, the apoptosis test, and CFU analysis among groups according to the duration of cryopreservation.

**Results**

The recovery rates of the TNC count, the CD34+ cell count, and cell viability did not differ significantly according to the duration of cryopreservation. ALDH analysis, the cell viability test, and the apoptosis test did not reveal any increasing or decreasing trend according to the duration of cryopreservation. Further, the numbers of CFU-granulocyte/macrophage and CFU-granulocyte/erythrocyte/macrophage/megakaryocyte did not differ significantly according to the duration of cryopreservation.

**Conclusion**

These results suggest that the quality of CB is not affected by cryopreservation for up to a period of 5 years.

**Key Words**

Cord blood, Cryopreservation, Quality

---

**INTRODUCTION**

In hematopoietic stem cell transplantation (HSCT), cord blood (CB) with a high total nucleated cell (TNC) count per unit is preferred after the selection of HLA-compatible CB unit(s) for a given recipient [1]. The TNC count is critical, because TNCs have been associated with the speed of engraftment and post-transplantation survival after HSCT. Therefore, the TNC count has been used as a selection criterion for CB units [2-4]. Because CD34+ cells have been associated with post-transplantation survival and graft-versus-host disease, the CD34+ cell count has also been considered an important criterion for selecting CB units, in addition to the TNC count [5-7].

CB units are cryopreserved in liquid nitrogen for several years until they are used for suitable recipients. Therefore, the quality of cryopreserved CB units should ideally be maintained during cryopreservation. Studies regarding the quality of CB units cryopreserved for a maximum of 23.5 years at CB banks in other countries have been reported [8-12].

Since 1992, when the New York Blood Center’s Cord Blood Program was founded [13], many CB banks have come into existence. In Korea, 17 CB banks, including three gov-
government-assigned public CB banks, have been operating with the permission of the Ministry of Health & Welfare, according to the law on the management and research of CB proclaimed in July 2011 [14, 15]. To date, no quality assessment of cryopreserved CB units has been conducted in domestic CB banks. Since May 2006, when the Seoul Metropolitan Government Public Cord Blood Bank (Allcord) was founded, approximately 26,000 CB units have been cryopreserved until July 2013.

In this study, we evaluated the quality of cryopreserved CB units according to the duration of cryopreservation, ranging from 1 year to 5 years, and investigated whether the quality of the cryopreserved CB units changed during cryopreservation.

### MATERIALS AND METHODS

#### Subject selection

Two hundred CB units unsuitable for allogeneic transplantation according to the Korean legislative guidelines were obtained from the Seoul Metropolitan Government Public Cord Blood Bank (Allcord). The 200 CB units were divided into 5 groups according to the duration of cryopreservation: 1 year, 40 units; 2 years, 41 units; 3 years, 39 units; 4 years, 41 units; and 5 years, 39 units. This study was approved by the Institutional Review Board at Boramae Hospital, after the study documents were reviewed.

#### CB collection, tests, and processes for cryopreservation

CB was collected in utero in the delivery room. CB processing and efficacy testing were performed according to the standard operating procedures of the Seoul Metropolitan Government Public Cord Blood Bank (Allcord), which were described in our previous report [16].

#### CB thawing and assessment of post-thaw CB parameters

After thawing the selected CB units in a 37°C water bath, the TNC and CD34+ cell counts, aldehyde dehydrogenase (ALDH) level, cell viability, apoptosis, and the number of colony-forming units (CFUs) were examined in the thawed CB samples from each selected bag. Data on the TNC count, the CD34+ cell count, and cell viability before freezing were retrieved from the bank’s database. Post-thaw testing was performed as described in our previous report [16].

#### ALDH analysis

ALDH-bright cells (ALDHbr cells), which show high ALDH activity, were stained with BODIPY-aminooacet-aldehyde (BAAA), the fluorescent substrate for ALDH (ALDEFLUOR; Aldagen, Durham, NC, USA). Erythrocytes were lysed using an ammonium chloride-based buffered solution. Cells were adjusted to a concentration of 1×10^6 cells/mL using ALDEFLUOR assay buffer (Aldagen). Aliquots of 1 mL each of the experimental cell suspension (experimental tube), and control cell suspension (control tube) were placed in labeled tubes and stained with 5 μL of BAAA at the same time. Control tube samples were additionally treated with 5 μL of diethylaminobenzaldehyde (DEAB), a specific inhibitor of ALDH. After incubation at 37°C for 40 min, the cell suspensions were stained with 10 μL of phycocerythrin (PE)-conjugated anti-CD34 (BD Biosciences, San Diego, CA, USA) and 5 μL of phycocerythrin cyanine 7 (PC7)-conjugated anti-CD45 (BD Biosciences) and refrigerated at 4°C for 20 min. After centrifugation at 250 g for 5 min at 4°C, the supernatant was removed, cell pellets were resuspended using 0.5 mL of ALDEFLUOR assay buffer (Aldagen), and tubes were capped and stored at 4°C until analysis by flow cytometry (FC-500; Beckman Coulter). From each sample, 50,000 CD45+ events were acquired. The background fluorescence of the ALDHbr cells was assessed by analyzing the extent of cell inhibition by DEAB in the control tube, and ALDHbr cells were gated from the cells in the experimental tube. ALDHbr cells among CD34+ cells (CD34+ALDHbr cells) and CD34+ cells among ALDHbr cells (ALDHbrCD34+ cells) were enumerated.

#### Cell viability test

The viability of TNCs was measured using 0.4% trypan blue staining and 7-aminoactinomycin D (7-AAD) by excluding the non-viable cells in the process of CD34+ cell enumeration. The viability of CD34+ cells was measured using 7-AAD.

#### Apoptosis tests

**Analysis of apoptotic cells among TNCs using caspase-3:** Cells were adjusted to a concentration of 10×10^5 cells/μL using phosphate buffered saline (PBS). A 100 μL aliquot of the cell suspension was placed in a test tube. Cells were stained with 20 μL of fluorescein isothiocyanate (FITC)-conjugated anti-CD45 (BD, Biosciences) for 15 min at room temperature in the dark. Erythrocytes were lysed using 2 μL of an ammonium chloride-based buffered solution. After washing, the cells were adjusted to a concentration of 1×10^6 cells in 500 μL of the Cytofix/Cytoperm solution (BD, Biosciences) and incubated for 20 min on ice. After centrifugation, cell pellets were washed twice, using 500 μL of PE-conjugated caspase-3 for 20 min at room temperature in the dark. After washing and suspending the cells in 500 μL of Perm/Wash buffer solution (BD, Biosciences), cells were analyzed by flow cytometry (FC-500; Beckman Coulter). From each sample, 50,000 events were acquired and analyzed.

**Analysis of apoptotic cells among CD34+ cells using annexin-V:**

Cells were adjusted to a concentration of 10×10^5 cells/μL using PBS. A 100 μL aliquot of the cell suspension was placed in a test tube. Cells were stained with 10 μL of PE-conjugated anti-CD34 (BD, Biosciences) and 5 μL of PC7-conjugated anti-CD45 (BD, Biosciences) for 15 min at room temperature in the dark. Erythrocytes were lysed using an ammonium chloride (NH4Cl)-based buffered solution. After washing, the cells were adjusted to a concentration of 1×10^6 cells in 100 μL of the annexin-V binding buffer (BD, Biosciences)
Table 1. The number of total nucleated cells (TNC) before and after cryopreservation and TNC recovery according to the duration of cryopreservation.

| Duration (years) | N | Number (×10^8/unit) | Recovery (%)<sup>a</sup> | P  |
|-----------------|---|----------------------|--------------------------|----|
|                 |   | Before freezing      | After thawing            |    |
| 1               | 40 | 10.2±3.9             | 10.7±4.0                 | 99.7±0.9 (96.1–100.0) |
| 2               | 41 | 7.1±2.6              | 7.5±2.6                  | 99.6±1.1 (95.2–100.0) |
| 3               | 39 | 7.0±1.8              | 7.0±1.9                  | 98.0±3.3 (88.0–100.0)  |
| 4               | 41 | 8.4±3.3              | 8.5±3.4                  | 97.4±3.3 (89.7–100.0)  |
| 5               | 39 | 8.1±3.1              | 7.9±3.0                  | 96.7±3.9 (87.9–100.0)  |

Plus-minus values (±) are standard deviation of the mean.
<sup>a</sup>While recovery after thawing was sometimes greater than 100%, we chose to use an upper limit of recovery of 100%.

Table 2. The number of CD34+ cells before and after cryopreservation and CD34+ cell recovery according to the duration of cryopreservation.

| Duration (years) | N | Number (×10^6/unit) | Recovery (%) | P  |
|-----------------|---|---------------------|--------------|----|
|                 |   | Before freezing     | After thawing |    |
| 1               | 40 | 3.3±1.6             | 2.2±1.1      | 67.8±12.8 (50.0–96.0) |
| 2               | 41 | 2.3±1.2             | 1.5±0.8      | 68.6±12.1 (42.3–98.4)  |

Plus-minus values (±) are standard deviation of the mean.

RESULTS

Comparison of results before and after cryopreservation

TNC recovery

Table 1 shows the TNC counts before freezing and after thawing and TNC recovery according to the duration of cryopreservation. TNC recovery significantly differed between the groups (P<0.001). Multiple comparison tests showed that TNC recovery was significantly higher in the 1-year and 2-year cryopreservation groups than in the 3-year, 4-year, and 5-year cryopreservation groups. However, there was no significant difference between the 1-year and 2-year cryopreservation groups or between the 3-year, 4-year, and 5-year cryopreservation groups.

CD34+ cells recovery

For consistency of data, we used the CD34+ data of only those samples that were analyzed using the same manufacturer’s kit and instrument before freezing and after thawing. These CD34+ cells were quantitated by a single-platform method, the International Society of Hemotherapy and Graft Engineering (ISHAGE) standard protocol, and FC-500 (Beckman Coulter). We analyzed CD34+ cell recovery in the CB units of the 1-year and 2-year cryopreservation groups.

Table 2 shows the number of CD34+ cells before freezing.
Quality of cryopreserved CB

and after thawing and CD34+ cell recovery of the 1-year and 2-year cryopreservation groups. CD34+ cell recovery was not different between the 1-year and 2-year cryopreservation groups (P=0.789), with cell-recovery values of approximately 68%.

Cell viability

Because the cell viability before freezing was measured using only trypan blue staining, the cell viability before freezing and after thawing was compared using cell viability based on trypan blue staining.

For all the CB units, the mean cell viability percentages before freezing and after thawing were 89.3% and 86.2%, respectively. Table 3 shows cell viability and the change in viability before freezing and after thawing, according to the duration of cryopreservation. To identify whether cell viability changed after cryopreservation according to the duration of cryopreservation, the changes in cell viability between before freezing and after thawing were compared according to the duration of cryopreservation, but no significant differences were observed (P=0.139).

Comparison of the results after thawing according to the duration of cryopreservation

Proportion of CD34+ cells, CD34+ALDH<sup>+</sup> cells, ALDH<sup>+</sup> cells, and ALDH<sup>+</sup>CD34+ cells

The percentages of CD34+ cells, CD34+ALDH<sup>+</sup> cells, ALDH<sup>+</sup> cells, and ALDH<sup>+</sup>CD34+ cells in the CB units, according to the duration of cryopreservation, are shown in Table 4. The percentages of CD34+ cells and ALDH<sup>+</sup> cells did not differ significantly between the groups (P=0.340 and P=0.501, respectively); however, the percentages of CD34+ALDH<sup>+</sup> cells and ALDH<sup>+</sup>CD34+ cells were significantly different between the groups (P=0.007 and P=0.027, respectively). Multiple comparison tests showed that the percentage of CD34+ALDH<sup>+</sup> cells in the 5-year cryopreservation group was significantly lower than the percentages in the 1-year and 3-year cryopreservation groups. Further, multiple comparison tests showed that the percentage of ALDH<sup>+</sup>CD34+ cells in the 3-year cryopreservation group was significantly higher than that in the 1-year cryopreservation group. However, a decreasing trend in the percentages of either CD34+ALDH<sup>+</sup> cells or ALDH<sup>+</sup>CD34+ cells was not observed with an increase in the duration of cryopreservation.

Cell viability

The viability of TNCs and CD34+ cells according to the duration of cryopreservation are shown in Table 4. TNC viability based on trypan blue staining significantly differed between the groups (P=0.009). Multiple comparison tests showed that the viability in the 5-year cryopreservation

---

### Table 3. Cell viability before and after cryopreservation according to the duration of cryopreservation.

| Duration (years) | N  | Before freezing | After thawing | \(\triangle\) Viability<sup>a</sup> | P     |
|------------------|----|-----------------|--------------|-----------------------------------|-------|
| 1                | 40 | 88.8±1.9        | 87.0±1.6     | 2.4±1.7                           |       |
| 2                | 41 | 89.2±1.9        | 86.0±3.0     | 3.4±3.0                           |       |
| 3                | 39 | 89.6±1.6        | 86.7±3.4     | 3.4±3.5                           | 0.139 |
| 4                | 41 | 89.8±2.0        | 86.4±1.9     | 3.7±2.3                           |       |
| 5                | 39 | 88.8±1.9        | 85.0±2.8     | 3.9±3.1                           |       |

<sup>a</sup>Plus-minus values (±) are standard deviation of the mean.

### Table 4. Comparative analysis of the results according to the duration of cryopreservation.

|                        | 1 year (N=40) | 2 years (N=41) | 3 years (N=39) | 4 years (N=41) | 5 years (N=39) | P  |
|------------------------|---------------|----------------|----------------|----------------|----------------|----|
| CD34<sup>+</sup> cells (%) | 0.11±0.06    | 0.14±0.11     | 0.15±0.11     | 0.16±0.12     | 0.13±0.10     | 0.340 |
| CD34<sup>+</sup>ALDH<sup>+</sup> cells (%)<sup>b</sup> | 78.0±13.0    | 75.5±14.8     | 77.6±11.2     | 74.4±13.1     | 67.9±14.0     | 0.007 |
| ALDH<sup>+</sup> cells (%)<sup>c</sup> | 0.15±0.08    | 0.17±0.11     | 0.17±0.11     | 0.17±0.12     | 0.14±0.10     | 0.501 |
| ALDH<sup>+</sup>CD34<sup>+</sup> cells (%)<sup>c</sup> | 65.2±12.3    | 68.1±15.7     | 75.6±12.9     | 69.2±15.9     | 66.7±15.9     | 0.027 |
| TNC viability          |               |               |               |               |               |     |
| Trypan blue (%)        | 87.0±1.6      | 85.9±3.0      | 86.7±3.4      | 86.4±1.9      | 85.0±2.8      | 0.009 |
| 7-AAD (%)              | 55.5±6.7      | 54.8±7.8      | 55.7±7.8      | 53.7±7.6      | 51.0±9.5      | 0.057 |
| CD34<sup>+</sup> cells |               |               |               |               |               |     |
| 7-AAD (%)              | 96.2±2.8      | 96.6±3.0      | 95.8±3.4      | 95.6±3.9      | 93.9±5.1      | 0.018 |
| Apoptosis              |               |               |               |               |               |     |
| TNC Caspase-3 (%)      | 4.3±1.9       | 5.0±2.6       | 5.5±2.7       | 5.0±1.8       | 4.5±1.8       | 0.163 |
| CD34<sup>+</sup> cells Annexin-V (%) | 3.9±4.0 | 4.2±3.0 | 4.9±3.3 | 3.8±2.7 | 7.9±5.5 | <0.001 |
| CFU-GEMM (×10<sup>5</sup>/unit) | 0.36±0.77 | 0.11±0.30 | 0.15±0.82 | 0.03±0.15 | 0.11±0.30 | 0.165 |
| CFU-GM (×10<sup>5</sup>/unit) | 2.48±3.59 | 2.27±2.74 | 2.00±2.17 | 1.22±1.47 | 1.02±1.44 | 0.076 |

<sup>b</sup>Cells with high ALDH activity among CD34<sup>+</sup> cells. <sup>c</sup>Cells with high ALDH activity. <sup>c</sup>CD34<sup>+</sup> cells among cells with high ALDH activity.

Abbreviations: ALDH, aldehyde dehydrogenase; TNC, total nucleated cells; 7-AAD, 7-aminoactinomycin D; CFU-GEMM, colony-forming unit-granulocyte/erythrocyte/macrophage/megakaryocyte; CFU-GM, colony-forming unit-granulocyte/macrophage.
group was significantly lower than that in the 1-year cryopreservation group. However, a decreasing trend was not observed with an increase in the duration of cryopreservation. TNC viability based on 7-AAD did not differ significantly according to the duration of cryopreservation ($P=0.165$). However the percentages of apoptotic CD34$^+$ cells differed significantly according to the duration of cryopreservation ($P<0.001$). Multiple comparison tests showed that viability was significantly lower in the 5-year cryopreservation group than in the 1-year and 2-year cryopreservation groups. However, a decreasing trend was not observed with an increase in the duration of cryopreservation.

**Proportion of apoptotic cells**

The percentages of apoptotic cells within the TNC and CD34$^+$ cell populations are shown in Table 4, and no significant differences were noted in the percentages of apoptotic TNCs according to the duration of cryopreservation ($P=0.163$). However the percentages of apoptotic CD34$^+$ cells differed significantly according to the duration of cryopreservation ($P<0.001$). Multiple comparison tests showed that the percentage of apoptotic cells was significantly higher in the 5-year cryopreservation group than in the other cryopreservation groups. However, a decreasing trend was not observed with an increase in the duration of cryopreservation.

**The numbers of CFU-GEMM and CFU-GM**

The numbers of CFU-GEMM and CFU-GM are shown in Table 4, and no significant differences were observed according to the duration of cryopreservation ($P=0.165$ and $P=0.076$, respectively).

**DISCUSSION**

In this study, which included a large number of CB units, we investigated whether the quality of CB was affected by cryopreservation.

CB is easily available for allograft transplant to suitable recipients during the HSCT procedure because CB units are cryopreserved, and hence, the quality of CB units as hematopoietic stem cell source, should be maintained during the cryopreservation period. In our previous study [17], we analyzed the proportion of cryopreserved CB units suitable for transplantation according to recipient weight with a criterion of a minimum TNC count of more than $2.0\times10^7$/kg before cryopreservation [5, 18]. The results of this previous study showed that whereas 100% of the cryopreserved CB units had a sufficient TNC count for recipients weighing less than 30 kg, only 12% of the cryopreserved CB units had a sufficient TNC counts for recipients weighing more than 60 kg [17]. For this reason, the TNC and CD34$^+$ cell counts in the CB units must be maintained during cryopreservation.

Some studies have reported on the quality assessment of cryopreserved CB units at CB banks in other countries, but these results differ to some extent [8-12]. Broxmeyer et al. [8-11] compared TNC recovery and the numbers of CFU-GEMM and CFU-GM before and after cryopreservation and found no significant differences after CB cryopreservation for a maximum of 23.5 years. Yamamoto et al. [12] reported that the TNC count, CD34$^+$ cell count, and CFU-GM number decreased after cryopreservation; however, recovery of the TNC count, CD34$^+$ cell count, and CFU-GM number did not differ significantly between CB units cryopreserved for 1 month and those cryopreserved for 10 years.

The CB units used in our study were stored for a maximum of 5 years, which is shorter than that reported in previous studies. However, while previous studies considered a small number of CB units (a maximum of approximately 20) in each group with varying durations of cryopreservation, our study was performed using a total of 200 CB units with approximately 40 units in each of the 5 groups of varying durations of cryopreservation.

TNC recovery was significantly higher in the 1-year and 2-year cryopreservation groups than in the 3-year, 4-year, and 5-year cryopreservation groups; however, the mean value of TNC recovery was more than 96.7% in all groups. Therefore, we speculated that there was no decreasing trend in TNC recovery with an increase in the duration of cryopreservation.

The number of CD34$^+$ cells enumerated differs according to the flow cytometry systems and counting methods [19]. Here, the numbers of CD34$^+$ cells enumerated using different flow cytometry systems and different counting methods were not significantly different. However, when CD34$^+$ cells were enumerated using the single-platform ISHAGE method, the CD34$^+$ cell count measured using FC-500 (Beckman Coulter) was higher than that measured using FACSCalibur (BD Biosciences). Additionally, when CD34$^+$ cells were enumerated using FACSCalibur (BD Biosciences), the CD34$^+$ cell count measured using the single-platform ISHAGE method was higher than that measured using the dual-platform ISHAGE method. In our study, the CD34$^+$ cell enumeration method used after thawing was different from that used before freezing in the 3-year, 4-year, and 5-year cryopreservation groups; therefore, we could not analyze whether CD34$^+$ cell recovery changed in these groups. However, CD34$^+$ cell recovery in the 1-year and 2-year cryopreservation groups was approximately 68%, in agreement with the findings of previous studies on CD34$^+$ cell recovery in cryopreserved CB and peripheral blood stem cells (PBSC) after thawing, although the duration of cryopreservation differed to some extent [12, 20]. The mean value of CD34$^+$ cell recovery was 72.7% in CB units cryopreserved for 1 month and 68.4% in CB units cryopreserved for 10 years [12]. CD34$^+$ cell recovery in PBSC products cryopreserved for a median of 142 days was 72.7% [20]. Currently, most CB banks have a criterion for the minimal TNC count suitable for cryopreservation. However, after the large number of CB units required to cover the diversity of HLA polymorphisms is secured, a criterion for the minimal number of CD34$^+$ cells suitable for cryopreservation would be needed.
If CD34+ cell recovery after cryopreservation, which was approximately 68% in our study, is considered when defining the minimal number of CD34+ cells suitable for cryopreservation, we would be able to store high-quality CB units for HSCT.

In this study, we introduced a cell-viability test using 7-AAD after thawing the CB units and found that the viability of TNC measured using 7-AAD was lower than that measured using trypan blue staining. Whereas the mean value of viability based on trypan blue staining exceeded 85.0% in all groups, the mean value of viability based on 7-AAD staining was 51.0%–55.7%. A previous study also described a discrepancy in values of TNC viability between trypan blue and 7-AAD and suggested that cell viability evaluations using 7-AAD are preferred [21]. The viability of CD34+ cells measured using 7-AAD exceeded 93.9% in all groups; therefore, we confirm that most CD34+ cells survive cryopreservation.

As new aspects, ALDH levels and apoptosis were examined in our study as parameters for assessing the cryopreserved CB unit quality. ALDH is highly expressed in primitive hematopoietic cells, and surface markers reflecting hematopoietic stem cell activity, such as CD34 and CD133, have been reported to be expressed on some fraction of ALDHbr cells [22]. According to previous studies, CD34+ALDHbr cells and ALDHbrCD34+ cells affect long-term xenograft and multi-lineage hematopoiesis [22-24]. Apoptotic CD34+ cells have been reported to be able to influence transplantation outcome [25]. Because annexin-V is attached to phosphatidylserine, which is translocated from the inner cell membrane to the outer cell membrane during early apoptosis, annexin-V is a marker of apoptotic cells. However, trypan blue and 7-AAD stain only dead cells because they only penetrate non-intact cell membranes [26, 27]. Caspase-3 activity is increased during apoptosis [28].

In the 5-year cryopreservation group of our study, TNC recovery, the change in cell viability, and the percentage of CD34+ALDHbr cells were low, and the viability of TNC based on trypan blue staining, the viability of CD34+ cells based on 7-AAD staining, and the percentage of apoptotic CD34+ cells were high, compared to the values in the other groups. Therefore, the quality of CB units cryopreserved for 5 years could be decreased. However, the mean value of TNC recovery was more than 96.7% in all groups, and the mean viability of CD34+ cells was more than 93.9% in all groups. In particular, the numbers of CFU-GEMM and CFU-GM, representing the clonogenic and proliferative potentials of hematopoietic stem cells [29, 30], did not significantly differ according to the duration of cryopreservation. Therefore, we suggest that there are no significant differences in the quality of CB units cryopreserved for up to five years, from a clinical perspective. Studies on the quality of CB units according to the duration of cryopreservation will be continued in our laboratory. In addition, future studies will be required to ascertain whether hematopoietic recovery after transplantation would be affected by the duration of cryopreservation of transplanted CB unit(s).

In summary, this study showed no significant changes in the quality of CB units over a maximum of 5 years of cryopreservation. This is the first study investigating the quality of CB units cryopreserved at CB banks in Korea. Through the results of our study, we expect that the reliability of cryopreserved CB units as a source of hematopoietic stem cells for HSCT will be improved.

ACKNOWLEDGMENTS

We thank all staff members of Allcord for their technical assistance, and we greatly appreciate the Korean mothers who voluntarily donated cord blood to The Public Cord Blood Bank.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-8.
2. Ballen K, Broxmeyer HE, McCullough J, et al. Current status of cord blood banking and transplantation in the United States and Europe. Biol Blood Marrow Transplant 2001;7:635-45.
3. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337:373-81.
4. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565-77.
5. Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000;96:2717-22.
6. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-8.
7. Schmitt N, Barrett J. Optimizing engraftment-source and dose of stem cells. Semin Hematol 2002;39:3-14.
8. Broxmeyer HE, Cooper S. High-efficiency recovery of immature hematopoietic progenitor cells with extensive proliferative capacity from human cord blood cryopreserved for 10 years. Clin Exp Immunol 1997;107(Suppl 1):45-53.
9. Broxmeyer HE, Hangoc G, Cooper S, et al. Growth characteristics and expansion of human umbilical cord blood and estimation of
its potential for transplantation in adults. Proc Natl Acad Sci U S A 1992;89:4109-13.

10. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 2011;117:4773-7.

11. Broxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson SA, Bodine DM. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A 2003;100:645-50.

12. Yamamoto S, Iiked A, Toyama D, et al. Quality of long-term cryopreserved umbilical cord blood units for hematopoietic cell transplantation. Int J Hematol 2011;93:99-105.

13. National Cord Blood Program at Howard P. Milstein Cord Blood Center. New York, NY: New York Blood Center, 2013. (Accessed August 22, 2013, at http://nybloodcenter.org/special-programs/national-cord-blood-program).

14. Cord blood banks operating under permission from the Ministry of Health Welfare. Seoul, Korea: Ministry of Health and Welfare, 2012. (Accessed August 22, 2013, at http://download.mw.go.kr/front_new/modules/download.jsp?BOARD_ID=1003&CONT_SEQ=266349&FILE_SEQ=113697).

15. Lee YH, Kim JY, Mun YC, Koo HH. A proposal for improvement in the utilization rate of banked cord blood. Blood Res 2013;48:5-7.

16. Lee HR, Park JS, Shin S, et al. Increased numbers of total nucleated and CD34+ cells in blood group O cord blood: an analysis of neonatal innate factors in the Korean population. Transfusion 2012;52:76-81.

17. Lee HR, Roh EY, Yoon JH, et al. Analysis of maternal and neonatal factors affecting hematopoietic parameters of cord blood. Korean J Blood Transfus 2009;20:1-13.

18. Kogler G, Callejas J, Sorg RV, Fischer J, Migliaccio AR, Wernet P. The effect of different thawing methods, growth factor combinations and media on the ex vivo expansion of umbilical cord blood primitive and committed progenitors. Bone Marrow Transplant 1998;21:233-41.

19. Ngoma A, Saito S, Ohto H, et al. CD34+ cell enumeration by flow cytometry: a comparison of systems and methodologies. Arch Pathol Lab Med 2011;135:909-14.

20. Castelhano MV, Reis-Alves SC, Vigorito AC, et al. Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. Transfus Apher Sci 2013;48:241-6.

21. Goodwin HS, Gruzinger LM, Regan DM, et al. Long term cryostorage of UC blood units: ability of the integral segment to confirm both identity and hematopoietic potential. Cytotherapy 2003;5:80-6.

22. Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells 2011;29:570-5.

23. Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006;107:2162-9.

24. Storms RW, Green PD, Safford KM, et al. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood 2005;106:95-102.

25. Shim JS, Cho B, Kim M, et al. Early apoptosis in CD34+ cells as a potential heterogeneity in quality of cryopreserved umbilical cord blood. Br J Haematol 2006;135:210-3.

26. Demchenko AP. The change of cellular membranes on apoptosis: fluorescence detection. Exp Oncol 2012;34:263-8.

27. Radke TF, Barbosa D, Duggleby RC, Saccardi R, Querol S, Kogler G. The assessment of parameters affecting the quality of cord blood by the appliance of the Annexin V staining method and correlation with CFU assays. Stem Cells Int 2013;2013:823912.

28. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999;6:99-104.

29. Pamphilon D, Selogie E, McKenna D, et al. Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative. Cytotherapy 2013;15:255-62.

30. Nawrot M, McKenna DH, Sumstad D, et al. Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative. Transfusion 2011;51:2001-5.